CTXR רווח למניה בשנים עשר החודשים האחרונים Citius Pharma

Citius Pharmaceuticals (CTXR) is moving toward the active rollout of oncology products into the US market. However, reliance on external capital and potential FDA delays create financial risks. Stability is provided by the high-margin hospital therapy niche. Rolling trailing twelve-month earnings per share visualizes these processes, and -2.10 shows the level of this metric.

To objectively assess the operational successes of Citius Pharmaceuticals (CTXR), investors must separate total profit from the impact of share issuance. This rolling earnings per share trend reflects the annual net income distributed across the total volume of securities. This metric allows for the measurement of real return on equity without accounting for dilution. By utilizing external CDMO facilities, Citius Pharmaceuticals (CTXR) minimizes capital expenditures, ensuring that the indicator's dynamics directly reflect the efficiency of the R&D cycle.